References
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA 2002;288:321–33
- Million Women Study Collaborators. Breast cancer and HRT in the Million Women Study. Lancet 2003;362:419–27
- Shapiro S, Farmer RD, Mueck AO, Seaman H, Stevenson JC. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. 2. The Women's Health Initiative: estrogen plus progestogen. J Fam Plann Reprod Health Care 2011;37:165–72
- Shapiro S, Farmer RD, Stevenson JC, Burger H, Mueck AO. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies. 4. The Million Women Study. J Fam Plann Reprod Health Care 2012 Jan 16. Epub ahead of print
- Kmietowicz Z. Articles disputing link between HRT and breast cancer are ‘ridiculous’. BMJ 2012;344:e513
- Cumming GP, Currie HD, Panay N, Moncur R, Lee AJ. Stopping hormone replacement therapy: were women ill advised?. >Menopause Int 2011;17:82–7
- British Menopause Society Council. Modernizing the NHS: observations and recommendations from the British Menopause Society. Menopause Int 2011;17:41–3
- Panay N, Ylikorkala O, Archer DF, Rakov V, Gut R, Lang E. Ultra low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:120–31
- Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260–8
- Harman SM, Brinton EA, Cedars M, . KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3–12
- Panay N, Fenton A. Has the time for the definitive, randomized, placebo-controlled HRT trial arrived? Climacteric 2011;14:195–6